Unaudited Condensed Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from Operating Activities:
Net loss	$ (385,450)	$ (84,033)
Adjustments to reconcile net loss to net cash used in operating activities
Unrealized (gain) loss on change in fair value of warrants	(92,746)	3,117
Interest earned on marketable securities held in Trust Account	(11,857)	(525)
Changes in current assets and current liabilities:
Prepaid expenses	19,500	(165,713)
Accrued liabilities	255,203	54,815
Due to related party	(1,816)	6,381
Net cash used in operating activities	(217,166)	(185,958)
Cash Flows from Investing Activities:
Investment held in Trust Account		(133,000,000)
Net cash used in investing activities		(133,000,000)
Cash flows from Financing Activities:
Proceeds from IPO and over-allotment		133,000,000
Payment of underwriting fees		(2,660,000)
Proceeds from private placement		4,160,000
Proceeds from issuance of promissory note to related party		125,000
Payment to promissory note to related party		(125,000)
Proceeds from issuance of common stock to initial stockholders		25,000
Payment of deferred offering costs		(375,347)
Net cash provided by financing activities		134,149,653
Net change in cash	(217,166)	963,695
Cash, beginning of the period	235,295
Cash, end of the period	18,129	963,695
Supplemental disclosure of cash flow information
Initial value of common stock subject to possible redemption		124,413,913
Reclassification of offering costs related to Public Shares		(4,779,936)
Accretion of common stock to redemption value		13,366,023
Accretion of common stock to redemption value (interest earned on trust account)	$ 11,857	525
Forfeiture of founder shares		13
Initial classification of warrant liability		270,307
Deferred offering costs included in accrued expenses		$ 50,000